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The presentation of endogenously synthesized pep-
tides in association with HLA class I molecules
allows the activation of CD8+ lymphocytes. Tumor
cells often fail to present antigenic peptides resulting
in the immune escape of metastasizing cells. The
aim of this study was to elucidate possible molecular
mechanisms leading to reduced antigen presentation
in melanoma. Melanoma cell short-time cultures
were genotypically and phenotypically HLA-typed
by sequence-speci®c primer polymerase chain reac-
tion and complement-mediated microlymphocyto-
toxicity assays, respectively. Flow cytometric analysis
of HLA-A2 and HLA-A3 allospeci®cities were per-
formed to con®rm typing results. Transcriptional
levels of classical HLA-A, HLA-B genes and nonclas-
sical HLA-G genes were detected using quantitative
real-time reverse transcriptase polymerase chain
reaction (LightCyclerÔ). We found loss or downre-
gulation of HLA proteins in 18% (for HLA-A) and
53% (for HLA-B) of all tested metastases. Genomic
analysis, however, revealed the presence of the cor-
responding HLA class I gene in six out of seven
cases. On the level of gene transcription we observed
a differential regulation of HLA-A, HLA-B, and
HLA-G mRNA expression. There was no correlation
between classical and nonclassical HLA gene tran-
scription, but the transcriptional levels of classical
HLA corresponded to the protein expression levels.
Furthermore, an overall reduced amount of HLA
class I gene transcription was observed in melanoma
metastases during disease progression in three indi-
viduals. We postulate that there is a transcriptional
regulation of HLA class I gene expression in mela-
noma cells. These data suggest that treatment
approaches aimed at activating speci®c cytotoxic T
lymphocytes are most successful in early disease. Key
words: HLA class I/malignant melanoma/nonclassical
HLA-G. J Invest Dermatol 117:1498±1504, 2001
T
he HLA class I complex is operative in almost all cells
and allows the immune system to monitor for the
presence of viral or tumor antigens. HLA class I
mainly presents peptides from endogenously hydro-
lyzed proteins. Display of peptides in an HLA-
restricted fashion activates speci®c cytotoxic T lymphocytes, which
kill the offending cells. Loss or downregulation of HLA proteins is
one of several mechanisms resulting in immune escape of
metastasizing cells (Marincola et al, 1994; Geertsen et al, 1998;
Hicklin et al, 1999). In melanoma, reduced HLA class I expression
correlates with a poor prognosis. The expression levels of HLA class
I and II molecules on the surface of tumor cells have been
extensively examined (Ferrone and Marincola, 1995; Garrido et al,
1997) and the following abnormalities were found in melanoma
cells: (i) nonfunctional b2-microglobulin (b2m) leads to a total loss
of HLA class I restricted recognition by cytotoxic T lymphocytes
(D'Urso et al, 1991; Hicklin et al, 1998); (ii) genomic loss resulting
in expression of only one HLA haplotype (Marincola et al, 1994);
(iii) locus-speci®c downregulation due to defects in the transporters
associated with antigen processing (Cromme et al, 1994; Keating et
al, 1995; Straten et al, 1997; Kamarashev et al, 2001); and (iv)
selective loss of HLA class I allospeci®cities, which impairs the
ability of a malignant cell to present a speci®c restriction element to
lymphocytes (Kageshita et al, 1993; Rivoltini et al, 1995; Luboldt et
al, 1996). Geertsen and coworkers showed that HLA-B protein
expression was the most downregulated in melanoma metastases
(Geertsen et al, 1998). We systematically screened melanoma short-
time cell cultures for loss of HLA-A and HLA-B alleles. As selective
loss of HLA class I complexes is frequently found in advanced
melanoma stages (Geertsen et al, 1998) and an increased suscept-
ibility to natural killer cell mediated lysis has been reported (Maio et
al, 1991), we were also interested to investigate whether
nonclassical HLA class I molecules are involved in immune escape
mechanisms (Paul et al, 1998). It is known that HLA-G can inhibit
natural killer cell activity and that it is expressed by some melanoma
metastases (Paul et al, 1999), although its contribution to
tumorigenesis is not yet clear. In this work we show, by using
quantitative real-time polymerase chain reaction (PCR) technology
(LightCyclerÔ), that a reduced expression of HLA-A and HLA-B
proteins in melanoma cells is more probably due to transcriptional
regulation than to HLA-gene-related alterations. In addition, we
show that consecutive melanoma metastases downregulate HLA
class I gene transcription during disease progression in three cases.
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MATERIALS AND METHODS
Melanoma cell cultures Melanoma cells were released and dissociated
from washed and fragmented tissue sections by serial incubation with
dispase (Boehringer, Mannheim, Germany) diluted 1:2 in RPMI 1640
(Gibco, Paisley, U.K.) and with collagenase (Sigma, St. Louis, MO)
diluted 1:100 in Tris-buffered saline containing 10 mM CaCl2.
Outgrowing melanoma cells were routinely cultivated as monolayers at
37°C and in a 5% CO2 atmosphere in RPMI 1640 supplemented with
10% heat-inactivated fetal bovine serum (Seromed, Berlin, Germany),
5 mM glutamine (Biochrom, Berlin, Germany), 1 mM sodium pyruvate
(Gibco), and 1% of an antibiotic mixture containing 10,000 U penicillin
per ml and 10,000 mg streptomycin per ml (Gibco) (Geertsen et al,
1998). Melanocytic origin of cell cultures was tested by measuring the
expression of MelanA, gp100, MAGE-3, and high molecular weight
melanoma associated antigen by reverse transcription PCR (RT-PCR).
Most of the cell cultures tested showed mRNA expression of at least one
up to all four tumor markers.
Fluorescence-activated cell sorter staining Approximately 5±
10 3 105 cells each were incubated with different antibodies at a
concentration of 2±4 mg per 106 cells in a total volume of 100 ml (2%
fetal bovine serum/phosphate-buffered saline) for 2 h on ice in the dark.
Then, cells were washed with phosphate-buffered saline and
unconjugated antibodies were stained with a 1:30 dilution of ¯uorescein-
coupled rabbit anti mouse IgG secondary antibody (Dako, Glostrup,
Denmark) for 1 h on ice in the dark. Biotinylated antibodies were
stained with ¯uorescein-conjugated streptavidin (Dako), diluted 1:50. In
all cases, cells were also stained with the appropriate isotype-matched
control antibodies, mouse IgG1, IgG2a, or IgM (Ancell, Bayport, MN).
After washing and ®xation with 0.5% formaldehyde in phosphate-
buffered saline, ¯uorescence was measured on a FACSCalibur machine
(Becton Dickinson, San Jose, CA). Nonviable cells were gated out. Flow
cytometric data are presented as the mean of ¯uorescence intensity versus
cell counts. The following primary monoclonal antibodies were used:
BB7.2 (ATCC HB-82; mouse IgG2b), which is speci®c for HLA-A2
allotype, and GAP-A3 (ATCC HB-122; mouse IgG2a), which is speci®c
for HLA-A3 allotype.
HLA phenotyping The HLA class I phenotype of all patients was
determined on blood samples collected in acidic citrate dextrose tubes
using a complement-mediated microlymphocytotoxicity test (Biotest,
Dreieich, Germany). This test was performed following the
manufacturer's instructions. The HLA class I phenotyping of melanoma
cell short-term cultures was also performed in this way with the
modi®cation that melanoma cells were pretreated with 500 U interferon-
a (IFN-a) per ml (Roferon, Hoffmann-LaRoche, Basel, Switzerland) for
40 h at 37°C in a 5% CO2 atmosphere to upregulate surface expression
of HLA class I molecules.
HLA genotyping The DNA of approximately 106 cultured melanoma
cells was isolated using standard methods. Then, 2 mg of DNA was used
for the sequence-speci®c primer PCR (SSP-PCR; Biotest) following the
manufacturer's instructions (Fig 1). This method is based on allele-
speci®c primers that bind only to completely complementary sequences
leading to a speci®c ampli®cation of individual HLA class I alleles
(Bunce et al, 1995).
Real-time quantitative RT-PCR Total RNA was isolated from
cultured melanoma cells using the RNAesy kit (Quiagen, Basel,
Switzerland). The quality of the RNA was monitored in a 2% agarose
gel. RNA was then reverse transcribed into cDNA. With primers
speci®c for the 3¢ and 5¢ untranslational region HLA-A and HLA-B gene
segments were selectively ampli®ed in a real-time quantitative PCR on a
LightCycler (Hoffmann-LaRoche) machine. Use of mixed primer pairs
(3¢-HLA-A + 5¢-HLA-B and 5¢-HLA-A + 3¢-HLA-B) showed no
ampli®cation product by RT-PCR, demonstrating their highly speci®c
binding for either HLA-A or HLA-B untranslational regions (data not
shown). Table I gives the primer sequences, their positions, and the
annealing temperatures used in the PCR. A Hot-Start PCR was
performed using 2 ml ready-to-use mastermix (LightCycler ± Faststart
DNA Master SYBR Green I, Roche Molecular Biochemicals,
Mannheim, Germany), containing thermostable recombinant Taq
polymerase, reaction buffer, dATP, dCTP, dGTP, dUTP, 0.5 mM of
each oligonucleotide primer (Microsynth, Balgach, Switzerland), variable
free MgCl2 concentrations, 2 ml cDNA, and water to a ®nal volume of
20 ml. After an initial denaturation step of 10 min to activate the
FastStart enzyme, ampli®cation occurred as a three-step cycling
procedure: denaturation at 95°C for 10 s, annealing at 48°C for 10 s,
and elongation at 72°C for 1 min, for 40 cycles. Finally, the temperature
was raised gradually (0.2°C per s) starting from 70°C to 99°C for the
melting curve analysis. External standards for the quanti®cation consisted
of four serial 1:2 dilutions of healthy donor peripheral blood
mononuclear cell (PBMC) cDNA obtained from one single preparation
that was added to every experiment. The ¯uorescence signal was plotted
against the cycle number for all samples and external standards. The Fit
Points method option was used in the course of analyzing and
Figure 1. Genotyping of cultured melanoma cells. Melanoma cell
short-term culture of patient 990802 was analyzed by SSP-PCR (Biotest)
and visualized on an agarose gel. Part (A) shows PCR results for HLA-A
allospeci®cities. Bands in position 1 (247 bp, A1) and 3 (230 bp, A3)
indicate the genotype (control bands »1000 bp). Part (B) shows PCR
results for HLA-B allospeci®cities. Bands in position 2 (215 bp) and 21
(688 bp) indicate B8; bands in position 4 (259 bp) and 13 (307 bp)
indicate B14; position 48 shows additionally control Bw6 (347 bp).
Table I. Primer sequences used for RT-PCRa
Sequenceb Name Position Annealing temperature (°C) Amplicon size (pb)
CCA GAC GCC GAG GAT GGC C HLA A 5¢UTc 632 in 5¢UT 48 1400
GAG CAC AGG TCA GCG TGG GAA G HLA-A 3¢UT 218 in 3¢UT
CCG GAC TCA GAA TCT CCT CAG HLA-B 5¢UT 615 in 5¢UT 44 1400
AAA CAC AGG TCA GCA TGG GAA C HLA-B 3¢UT 218 in 3¢UT
CAA TGT GGC TGA ACA AAG GA HLA-G 5¢ 522 (exon 3) 60 419
CCA GCA ACG ATA CCC ATG HLA-G 3¢ 940 (exon 5)
CGA CAA CGG CTC CGG CAT GTG C b-actin 5¢ 71 (exon 1) 66 420
CGT CAC CGG AGT CCA TCA CGA TGC b-actin 3¢ 490 (exon 2)
aAll primer pairs are especially designed for RT-PCR analysis on LightCyclerÔ. The primers are intron-spanning and gave no ampli®cation with genomic DNA (data
not shown).
bSequences are given 5 ¢to 3¢.
cUT, untranslated region.
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quantifying data, allowing the de®nition of a noise band and subsequent
background ¯uorescence subtraction, and resulting in the display of only
log-linear and plateau ampli®cation phases. The point when the signal
rose above the background level, the so-called ``crossing-point'', was
then determined for each standard dilution. A standard curve was
generated for each run, plotting the crossing-point against the log
concentration of the standards. Normalization of estimated HLA-A,
HLA-B, and HLA-G amounts was achieved by calculating the ratios
between HLA and b-actin in order to compensate the variations in
quantity and quality of starting mRNA. Ten microliters of each
ampli®cation product were then checked by electrophoresis on a 2%
agarose gel stained with ethidium bromide. The estimated size of the
ampli®ed fragments matched the calculated size. Product identity was in
parallel checked by melting curve analysis, which is another application
in the LightCycler analysis program.
RESULTS
Low expression of HLA class I proteins on the surface of
melanoma metastases A total of 32 melanomas were analyzed
comprising four primary tumors, 13 lymph node metastases, and 15
remote metastases. The HLA class I phenotypes of all tested patients
are shown in Table II. The HLA class I allospeci®cities were
determined on autologous PBMC and subsequently on melanoma
cell cultures after incubation with IFN-a. Some cultures were
analyzed several times over a period of 6 mo. The results did not
vary during the cultivation. The microlymphocytotoxicity test
performed with stimulated melanoma cells, however, appeared
more dif®cult to evaluate than the typing of PBMC. IFN-a
stimulation of melanoma cells was necessary to increase the
sensitivity of the microlymphocytotoxicity test above background
level. We are aware of the fact that analyses in different cell culture
conditions were being compared. We found that preferentially
HLA-B is downregulated on the melanoma cell surface (53% of
HLA-B compared to 18% of HLA-A allotypes). In some cases,
melanoma cells were tested in SSP-PCR for genetic background to
determine whether genetic aberrations may be the reason for loss of
allospeci®cities (Fig 1). Except for one metastasis, all tested
melanomas (n = 7) displayed the HLA gene locus expected from
the PBMC typing results (n = 31). Among the HLA-B losses we
found no preference for any HLA-B allospeci®cities. It is
noteworthy that melanomas in advanced stages in general grew
faster in our short-term cultures than primary tumors. In ®ve
metastases the HLA-A2 and HLA-A3 surface expression was tested
in ¯ow cytometry analysis without prior IFN-a stimulation
(Fig 2). The tumor 990825 showed complete loss of HLA-A2
expression, whereas HLA-A3 was clearly detectable (patient A).
The tumors 970917 and 961121 are metastases from the same
patient (patient B). The metastasis 970917 showed normal HLA-A2
and HLA-A3 expression compared to reduced protein expression
of both allospeci®cities on metastasis 961121. Similar results were
obtained for patient C. The ®rst metastasis (960312) expressed
HLA-A3 on the surface, whereas the other (970325) displayed no
detectable HLA-A3 on the cell surface.
Differential transcription of classical and nonclassical HLA
genes in melanoma cells After evaluating HLA surface
expression in melanoma cells, we asked whether differences are
also present at the transcriptional level. Therefore, RNA of
approximately 5 3 107 unstimulated melanoma cells was isolated
and subjected to RT-PCR analysis. In order to evaluate
transcriptional levels in more detail we used real-time PCR
technology (LightCyclerÔ), allowing us to quantify cDNA
compared to a relative external standard. Figure 3 gives a
Table II. Surface expression of HLA allotypes on melanoma cells compared to peripheral blood lymphocytes
No. Patient Tumor stagea HLA-A allotype (blood) Expression on melanomab HLA-B allotype (blood) Expression on melanomab
1 960704 I 1 ++ 47/63 ±/++
2 961121 I 2/3 ±/+ 35/38 ±/++
3 961122 I 1/11 +/++ 8/35 ++/±
4 980923c I 1/23 ++/++ 57 ++
5 950320 II 26/32 ++/++ 27/44 ++/±
6 950526 II 1/2 ±/++ 13/60 ++/++
7 950822c II 1/2 ++/± 13/60 ++/±
8 960312 II 1/3 +/++ 8/62 ++/+
9 960507 II 2 + + 7/60 ±/++
10 961127 II 2/25 ++/++ 44/58 +/++
11 970325 II 1/3 ±/+ 8/62 ±/±
12 970917 II 2/3 ++/++ 35/38 +/±
13 990202c II 1/23 ++/+ 57 ++
14 990802c II 1/3 +/++ 8/65 +/±
15 990820 II 11 ++ 44/56 +/++
16 990831 II 2/23 ++/+ 8/49 +/+
17 990922 II 2/24 +/++ 8/41 ++/++
18 960306 III 1/32 +/++ 8/35 ±/+
19 960618 III 2/28 ++/+ 8/44 ++/±
20 960924 III 2/3 ++/++ 7/49 ++/+
21 970207 III 2/3 +/++ 7/51 ±/+
22 970526 III 2 + + 35/61 +/++
23 970603 III 2/3 +/++ 7/51 ±/+
24 980513 III 1 ++ 8 +
25 990416 III 3/31 ++/+ 35/60 ±/++
26 990420 III 1/32 +/++ 52/57 ++/++
27 990715c III 3/31 ++/++ 35/60 ±/++
28 990719 III 24 + 13/60 ++/++
29 990728 III 1 ++ 13/58 +/+
30 990825c III 2/3 ±/++ 38/41 +/++
31 990901 III 1/2 ++/++ 7/49 +/++
32 990921c III 32/68 ±/+ 7/44 +/±
aI, primary melanoma; II, lymph node metastasis; III, remote metastasis.
b++, same expression as observed on peripheral blood lymphocytes; +, reduced expression; ±, no expression detectable in melanoma.
cAllospeci®cities were tested additionally in SSP-PCR.
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representative example of an HLA-A analysis. Real-time
¯uorescence RT-PCR enabled us to monitor on-time DNA
ampli®cation. In each experiment serially diluted cDNA from
healthy donor PBMC was included as a relative standard (Fig 3,
black symbols). All samples were ampli®ed with b-actin primers to
evaluate and normalize the amount of cDNA subjected to the
HLA-A, HLA-B, and HLA-G RT-PCR. Figure 4 shows a
selection of samples tested for HLA-A, HLA-B, and b-actin. The
RT-PCR was stopped at a cycle demonstrating logarithmic cDNA
ampli®cation. The PCR products were separated by migration
through a 2% agarose gel. Differential HLA-A and HLA-B
transcription became already apparent at that stage of
conventional log-phase detection. A more precise analysis
covering a wider dynamic range is given in Fig 5 where relative
amounts of HLA transcripts were normalized to b-actin and
expressed as a ratio of HLA-A versus b-actin (panel A), HLA-B
versus b-actin (panel B), or HLA-G versus b-actin (panel C).
Heterogeneous HLA gene transcription was observed in all
different tumor stages tested. The expression range covered three
log-phases. Statistical analysis using StatView (SAS Institute, Cary,
NC) revealed no signi®cant correlation between HLA-A/-B and
HLA-G gene transcription (HLA-A mRNA versus HLA-G
mRNA, correlation 0.323, p = 0.11; HLA-B mRNA versus
HLA-G mRNA, correlation 0.207, p = 0.32). In contrast
HLA-A mRNA levels were similar to HLA-B mRNA levels
(correlation 0.664, p < 0.01). Additionally, detected transcription
patterns resembled those found for HLA-A and HLA-B protein
expression (HLA-A mRNA versus HLA-A protein, correlation
0.365, p = 0.03; HLA-B mRNA versus HLA-B protein, correlation
0.306, p = 0.08) (Table II). In general, HLA-G was transcribed at
Figure 2. Low HLA-A expression on melanoma metastasis.
Melanoma cell short-time cultures of HLA-A2/-A3 haplotype (990825,
970917, 961121) were stained for both allospeci®cities with ¯uorescence
monoclonal antibodies (bold lines). The cultures 960312 and 970325 were
stained only for HLA-A3 monoclonal antibodies (bold lines). Cells were
measured in a ¯ow cytometer and analyzed with CellQuest (Becton
Dickinson) software. Appropriate isotype-matched controls are presented
in ®lled gray curves.
Figure 3. HLA-A cDNA ampli®cation with quantitative RT-PCR
(LightCycler). On-time monitoring of cDNA ampli®cation by
incorporation of CYBR Green dye. Gray curves represent melanoma-
derived cDNAs. Black curves represent normal PBMC-derived cDNA
from one preparation in 2-fold dilutions and serve as a relative standard
in each experiment. A linear regression of the standard is shown in the
inset.
Figure 4. Differential transcription of HLA-A and HLA-B genes
visualized in agarose gel electrophoresis. As an example, 13 cDNA
samples of melanoma cell short-time cultures were tested in RT-PCR
(LightCycler) for HLA-A, HLA-B, and b-actin. Then, the reaction was
stopped at a cycle showing linear growth on a logarithmic scale and the
probes were separated in a 2% agarose gel electrophoresis followed by
visualization of the bands with ethidium bromide staining.
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very low levels in comparison with classical HLA class I genes
(about 1000 times less). A ratio of HLA-G/b-actin larger than
0.001 was found only for three out of 25 melanoma metastases (Nos
5, 21, 28). The three melanoma metastases did not display
remarkably reduced transcription of HLA-A or HLA-B genes,
however.
Low levels of HLA class I gene transcription in late-stage
melanoma metastases In addition to single measurements of
HLA transcription levels of melanoma metastases we were
interested in a follow-up of melanoma patients. Figure 6
compares HLA-A and HLA-B transcriptional levels of three
patients with melanoma metastases obtained 1 y apart. In all three
cases the latest metastases displayed an overall reduced level of HLA
gene transcription. Even though the differences were not
statistically signi®cant (p = 0.2), the tendency of HLA
downregulation is apparent. This gradual decrease of HLA class I
gene transcription appeared to be independent of the individual
losses of allospeci®cities.
DISCUSSION
The HLA status of a tumor is critical for its recognition and
rejection by the immune system. In melanoma, the expression
levels of pan-HLA class I and pan-HLA class II proteins has
prognostic implications (van Duinen et al, 1988). A detailed
knowledge of the HLA status including allospeci®cities is a
precondition for a successful immunotherapeutical intervention.
This is especially true if peptides, peptide-pulsed dendritic cells
(Nestle et al, 1998), or genetically engineered tumor cells (Osanto et
al, 2000) are used as vaccines.
Restifo et al (1996) studied melanoma cell cultures obtained from
patients undergoing immunotherapy for metastatic melanoma.
Four out of 13 (31%) melanoma cell lines lacked functional HLA
class I expression as measured by ¯ow cytometry and immunohis-
tochemistry. Northern blot analysis of RNA extracted from these
cells revealed normal levels of a-chain mRNA but no b2m mRNA
or protein. Previous tumor sections obtained from patients prior to
immunotherapy were found to be positive for b2m, suggesting that
the loss of b2m may be a mechanism whereby tumor cells can
acquire immunoresistance during immunotherapy. b2m mutations
have been studied in several melanoma-derived cell lines and were
found to be heterogeneous, but all leading to the same end result,
namely a complete HLA class I antigen loss associated with tumor
progression (Hicklin et al, 1998).
Marincola et al (1994) evaluated HLA class I expression in 24
metastatic melanoma cell lines. Total loss of HLA class I expression
was not noted; instead, a variable degree of expression of HLA-B
was found that could be upregulated by IFN-g. HLA-A
allospeci®cities were consistently expressed in all cell types. Loss
of allelic expression was noted in two of 14 HLA-A2 (14%) and in
one of three HLA-A29 (33%) positive melanoma cell lines and
included a full haplotype, which suggests loss of a genomic
fragment. A loss of HLA-B allospeci®cities was not observed.
Another group demonstrated that the HLA-A2 loss in two
melanoma cell lines is due to genomic deletions within the
HLA-A2 coding gene, which cause lack of their transcription
(Wang et al, 1998). Moreover, they found a low TAP1 (transporter
associated protein 1) expression and proposed multiple defects as a
reason for loss or downregulation of HLA class I alleles.
In the adjuvant clinical situation, IFN-a, at least at high doses,
seems to improve the survival of high-risk melanoma patients, in
contrast to IFN-g (Kirkwood et al, 1996). It may be speculated that
this is due to enhanced HLA class I expression. Increased HLA class
I expression was found to correlate with a low relapse rate in
melanoma patients (van Duinen et al, 1988). Irrespective of the role
of HLA class I antigens in the clinical course of the disease, defects
in their expression by melanoma cells are likely to hamper T-cell-
based immunotherapy of melanoma (Maeurer et al, 1996). In vitro
data convincingly argue that HLA class I expression in melanoma
lesions might represent an important criterion to select patients for
Figure 5. Comparison of classical and nonclassical HLA gene
transcription in melanoma metastasis. Transcriptional levels of 32
cDNA samples are expressed as ratios of HLA-A (A), HLA-B (B), and
HLA-G (C) mRNA versus b-actin mRNA. The amount of b-actin
cDNA could be quanti®ed with an absolute b-actin plasmid standard. The
theoretical gain of 1 (ratio = 1) corresponds to 2.7 3 107 copies of
b-actin. All tests were done at least in triplicate. Error bars represent the
SEM of three to six individual experiments for each sample subsequently
divided by the corresponding value of b-actin. I signi®es primary tumors,
II lymph node metastasis, and III remote metastasis.
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T-cell-based therapy including vaccination approaches (Jager et al,
1997; Nestle et al, 1998).
As the defects in HLA class I expression can have various
molecular causes, we focused our study on transcriptional levels. By
using real-time PCR technology (LightCyclerÔ) we have been
able to quantify HLA class I gene transcription. The differential
HLA gene transcription re¯ects perfectly the heterogenicity of
melanoma metastases as they were presented in vivo. This includes
shape, size, and growth of tumors as well as differential expression
of melanoma-associated antigens (Hofbauer et al, 1998a±c). Because
of the high proliferative activity of melanoma cells, the outgrowth
of escape mutants frequently occurs. According to our experiments,
escape mutants often display a loss of, or at least reduced, HLA
expression (Geertsen et al, 1998). Here we present evidence that the
widespread reduced HLA class I protein expression observed is due
to low transcriptional levels. It has been shown previously that the
corresponding promoter contains cis-regulatory elements located
13±33 bp downstream of the transcription initiation site that
mediates HLA-B locus-speci®c downregulation in human mela-
noma (Grif®oen et al, 1999). Similar regulatory mechanisms were
also observed for MHC class II in melanoma. Lee et al (1999)
demonstrated that MHC class II expression in melanoma cell lines
is transcriptionally regulated by promoter activity. Recently
published data by Gridlestone (2000) showed the cooperation of
multiple transcription factors in HLA class I expression including
involvement of CIITA.
Our data support observations made for nonclassical MHC class I
HLA-G antigen transcription and expression (Paul et al, 1998).
HLA-G is known to play a role in tolerance of the semiallogeneic
fetus by the maternal immune system (Ober, 1998). Therefore,
HLA-G expression can aid tumor cells escaping from immuno-
surveillance by the host. As reported by Paul et al (1999), 12 out of
18 melanoma patients displayed higher amounts of HLA-G mRNA
transcripts in the tumor tissue compared to autologous healthy skin
samples. We found elevated HLA-G mRNA levels only in three
out of 25 melanoma metastases, however, and no inverse
correlation with classical HLA mRNA levels was detectable. It is
more likely that HLA-G expression is an independent characteristic
of individual melanoma metastases.
It is our understanding that HLA class I downregulation in
melanoma metastases occurs at the level of gene transcription, and
preferentially affects allospeci®cities suitable for tumor-associated
antigen presentation. In addition, a nonsigni®cant but apparent
general downregulation of HLA class I transcripts occurs, as
demonstrated in a long-time follow-up study of three patients.
Transcription factors such as NF-kB or enhancer A, the latter is
responsible for constitutive transcription of HLA class I, are possible
candidates involved in HLA gene regulation. It appears that
reduced HLA gene transcription represents a frequent escape
mechanism of melanoma metastases. Therefore, deeper insight into
HLA transcriptional regulatory mechanisms will become most
valuable for future melanoma therapies, which involve immune
recognition of melanoma cells by the host. Based on our data, we
recommend that speci®c vaccination therapies be used in early-
stage melanoma.
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